Journal of Clinical and Aesthetic Dermatology

DEC 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/918586

Contents of this Issue

Navigation

Page 22 of 59

23 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY December 2017 • Volume 10 • Number 12 O R I G I N A L R E S E A R C H 84.7%; n=63) for the face/chest group, 76.3 percent (95% CI 66.7%, 83.1%; n=63) for the scalp group, and 69.1 percent (95% CI 60.3%, 76.0%; n=62) for the trunk/extremities group (Figure 5). Similar results were seen for the reduction from baseline to Week 4 for the face/chest group (81.2% [95% CI 74.7%, 86.1%; n=63]), the scalp group (78.8% [95% CI 71.6%, 84.1%; n=63]), and the trunk/ extremities group (59.0% [95% CI 50%, 66.3%; n=62]). The reduction in AK lesion count from baseline to Week 8 for hypertrophic/ hyperkeratotic lesions was 68.5 percent (95% CI 4.5%, 89.6%; n=9) for the face/chest group, 62.5 percent (95% CI 13.2%, 87.5%; n=10) for the scalp group, and slightly lower for the trunk/extremities group at 39.2 percent (95% CI 7.9%, 59.9%; n=16). Similar results were observed for the mean percent reduction in AK lesion count of hypertrophic/hyperkeratotic lesions from baseline to Week 4 (face/chest, 78.7% [95% CI 38.7%, 92.6%; n=9]; scalp, 58.1% [95% CI 6.8%, 81.2%; n=10]; and trunk/extremities, 36.0% [95% CI 1.3%, 58.5%; n=16]). For nonhyperkeratotic/hypertrophic lesions, AKCLEAR 100 at Week 8 was achieved in 36.5 percent of patients in the face/chest group, 39.7 percent of patients in the scalp group, and 22.6 percent of patients in the trunk/ extremities group (Figure 6). Comparable values were seen at Week 4 for the face/chest group (36.5%), scalp group (31.7%), and trunk/extremities group (14.5%). AKCLEAR 100 at Week 8 for the hyperkeratotic/hypertrophic lesions was achieved in five of nine (55.6%) patients in the face/chest group, six of 10 (60.0%) patients in the scalp group, and four of 16 (25.0%) patients in the trunk/extremities group. For nonhyperkeratotic/hypertrophic lesions, AKCLEAR 75 at Week 8 was achieved in 71.4 percent of patients in the face/chest group, 65.1 percent of patients in the scalp group, and 50.0 percent of patients in the trunk/extremities group (Figure 7). Comparable levels were observed at Week 4 for the face/chest (76.2%) and scalp (74.6%) groups, but were slightly lower in the trunk/extremities group (37.1%). A detailed analysis of cosmetic outcomes, patient treatment satisfaction, and treatment adherence from this trial can be found in the study by Berman et al. 15 FIGURE 4. Individual local skin response (LSR) components by visit TABLE 3. Treatment-related AEs reported in ≥3% of patients in any treatment group TYPE FACE/CHEST 0.018% (n=63) SCALP 0.037% (n=63) TRUNK/EXTREMITIES 0.1% (n=62) Application site pain 28 (44.4%) 34 (54.0%) 26 (41.9%) Application site pruritus 18 (28.6%) 23 (36.5%) 21 (33.9%) Application site discomfort 1 (1.6%) 1 (1.6%) 2 (3.2%) Periorbital edema 2 (3.2%) 3 (4.8%) 2 (3.2%) Eyelid edema 0 2 (3.2%) 0 Headache 1 (1.6%) 2 (3.2%) 0 Erythema 0 0 2 (3.2%) SCC of skin 0 0 2 (3.2%) AEs: adverse events; SCC: squamous cell carcinoma

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - DEC 2017